Clotrimazole

證據等級: L5

預測適應症: 3 個

Clotrimazole: From Fungal Infections to Acne

One-Sentence Summary

Clotrimazole is a broad-spectrum imidazole antifungal well-established for treating candidal and dermatophyte infections including tinea pedis, oropharyngeal candidiasis, and vulvovaginal candidiasis. The TxGNN model’s highest-ranked prediction is Acne (disease) with a score of 99.86%, yet this direction is supported by only 1 suspended multi-component trial and no published literature, yielding a Hold recommendation. Critically, the second-ranked prediction — Vulvovaginitis — carries far stronger support with 22 clinical trials and 20 publications at Evidence Level L1, warranting a Proceed with Guardrails decision.

Quick Overview

Item	Content
Original Indication	Fungal/candidal infections (tinea pedis, oropharyngeal candidiasis, vulvovaginal candidiasis)
Predicted New Indication (Rank 1)	Acne (disease)
TxGNN Prediction Score	99.86%
Evidence Level	L4
Canada Market Status	Not marketed (0 DINs on file — likely data gap)
Number of DINs	0
Recommended Decision	Hold (Acne) / Proceed with Guardrails (Vulvovaginitis)

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the current Evidence Pack. Based on published literature (Crowley & Gallagher, J Applied Microbiology, 2014), Clotrimazole is a synthetic imidazole that inhibits cytochrome P450-dependent lanosterol 14α-demethylase, blocking ergosterol biosynthesis and disrupting fungal cell membrane integrity. This mechanism underpins its proven efficacy against Candida albicans and dermatophytes.

The mechanistic link to acne is biologically weak. Acne vulgaris is primarily driven by Cutibacterium acnes (a Gram-positive bacterium), excess sebum production, follicular hyperkeratinization, and inflammation — not fungal organisms. While Malassezia species (a yeast) cause Malassezia folliculitis, a condition that can mimic acne, this is a clinically distinct entity and not typical acne vulgaris. The high TxGNN score likely reflects shared knowledge-graph features — sebaceous glands, follicular units, skin microbiome signatures — rather than a direct pharmacological relationship.

Key observation for the second-ranked prediction (Vulvovaginitis): Clotrimazole’s antifungal mechanism directly targets Candida albicans, the pathogen responsible for 70–90% of vulvovaginal candidiasis cases. The repurposing rationale in this Evidence Pack explicitly notes this represents Clotrimazole’s original indication rather than a novel use. The Guardrails caveat stems from the fact that “vulvovaginitis” is a broader clinical category encompassing bacterial vaginosis and trichomoniasis, conditions where Clotrimazole has no antifungal efficacy.

Clinical Trial Evidence — Acne (Rank 1 · L4 · Hold)

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01244256	Phase 2/3	Suspended	80	Evaluates triple combination (Beclomethasone 0.025% + Gentamicin 0.1% + Clotrimazole 1%) for contaminated dermatosis with bilateral symmetrical lesions; Clotrimazole is one of three components and not the primary agent; trial was suspended prior to completion — no efficacy conclusions possible

Currently no dedicated standalone Clotrimazole trials for acne vulgaris are registered on ClinicalTrials.gov.

Clinical Trial Evidence — Vulvovaginitis (Rank 2 · L1 · Proceed with Guardrails)

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02242695	Phase 4	Completed	150	Head-to-head: Dequalinium chloride 10 mg vs Clotrimazole 100 mg vaginal tablet for VVC; direct efficacy, safety, and patient satisfaction comparison — highest direct relevance
NCT00313131	Phase 3	Completed	1,524	Large RCT in West Africa: single-dose Tinidazole+Fluconazole vs Metronidazole+Clotrimazole (3-day vaginal course) for vaginal discharge syndrome; Clotrimazole is a core component of the active treatment arm
NCT00755053	Phase 3	Completed	466	Non-inferiority: Clotrimazole ovule 500 mg vs vaginal tablet 500 mg for vaginal candidiasis; demonstrates formulation flexibility
NCT02180828	Phase 4	Completed	240	Clotrimazole vaginal tablet vs Fluconazole for severe VVC; evaluates efficacy and safety in severe presentation
NCT03562156	Phase 3	Completed	438	Oteseconazole vs placebo for recurrent VVC; Clotrimazole serves as standard-of-care reference, establishing benchmark efficacy for comparison
NCT03599323	N/A	Completed	1,033	Post-marketing safety surveillance of Empecid L Cream (Clotrimazole 1%) under pharmacist guidance; real-world safety profile
NCT03005353	Phase 2/3	Completed	100	Cumin seed extract vs Clotrimazole vaginal suppositories for candidal VVC; Clotrimazole serves as gold-standard active comparator
NCT04699240	Phase 4	Completed	140	Clotrimazole vaginal tablet ± oral Lactobacillus for preventing RVVC recurrence; evaluates adjunct microbiome strategy
NCT02860845	Phase 4	Completed	48	Boric acid + probiotics vs standard antifungal for VVC/bacterial vaginosis; provides management context for refractory cases
NCT06835361	Phase 2/3	Recruiting	264	Clotrimazole + Lactulose vs Clotrimazole monotherapy for candidal vulvovaginitis; superiority trial — ongoing

Literature Evidence — Vulvovaginitis (Rank 2 · L1)

PMID	Year	Type	Journal	Key Findings
41765149	2026	RCT	Complementary Therapies in Medicine	Clotrimazole vaginal cream vs Prangos ferulacea for VVC; comparative clinical and mycological cure rates
39824974	2025	RCT (triple-blind)	Scientific Reports	Mycozin vs Clotrimazole 1% cream for vaginal candidiasis (n=126); non-inferiority design; confirms Clotrimazole as benchmark standard
30565745	2019	RCT	Mycoses	Probiotics + lactoferrin as maintenance therapy for recurrent VVC; Clotrimazole as backbone treatment in trial context
2644595	1989	Clinical Trial	Obstetrics & Gynecology	Clotrimazole 500 mg weekly for recurrent VVC (n=42): 90.4% clinical remission, 83% mycologic cure; monthly prophylaxis evaluated prospectively
3895960	1985	RCT	American Journal of Obstetrics & Gynecology	Single-dose Clotrimazole 500 mg vs 6-day 100 mg course for candidal VVC (n=199); both regimens comparable in cure rates
24863842	2014	Review	Journal of Applied Microbiology	Comprehensive review: Clotrimazole as pharmaceutical — mechanism, VVC/tinea indications, resistance patterns, and emerging uses
39419780	2024	Observational	Journal of Applied Microbiology	Clotrimazole-induced shifts in vaginal bacteriome and lipid metabolism post-treatment; mechanistic insights into microbiome recovery
31106557	2019	Review	Minerva Ginecologica	Combined fluconazole (systemic) + metronidazole + clotrimazole (topical) strategy for RVVC long-term prophylaxis
1877264	1991	Clinical Study	DICP: Annals of Pharmacotherapy	Fluconazole vs Clotrimazole vaginal tablets for Candida vaginitis (n=90 evaluable/arm); comparable asymptomatic rates at 7–10 days
21774671	2011	Review	Journal of Women’s Health	Boric acid evidence review for RVVC; positions Clotrimazole as the established first-line azole against which alternatives are measured

Canada Market Information

No Drug Identification Numbers (DINs) are recorded in the current dataset, and market status is listed as Not marketed.

Important data gap: Clotrimazole-containing products — most notably Canesten® (Bayer Consumer Health) — are widely available in Canada as both prescription and OTC products. The 0-DIN result almost certainly reflects a collection gap rather than true absence from the Canadian market. A direct search of the Health Canada Drug Product Database (DPD) at health-products.canada.ca is required before making any regulatory decisions.

Safety Considerations

Please refer to the package insert for safety information. Full key warnings, contraindications, and drug interaction data were not available in this Evidence Pack and must be retrieved from the Health Canada product monograph or the TFDA package insert PDF.

Conclusion and Next Steps

**Decision: Hold (Acne · Rank 1)

Proceed with Guardrails (Vulvovaginitis · Rank 2)**

Rationale:

Acne (Rank 1 TxGNN, L4): Despite the highest prediction score (99.86%), the mechanistic basis for Clotrimazole in acne vulgaris is biologically weak. Cutibacterium acnes is not a fungal target. The only supporting trial was suspended, enrolled 80 patients, and evaluated Clotrimazole as one of three combination ingredients. No standalone evidence exists. The high score likely reflects knowledge-graph proximity between fungal folliculitis and acne rather than pharmacological relevance.
Vulvovaginitis (Rank 2 TxGNN, L1): Multiple completed Phase 3 and Phase 4 RCTs, large post-marketing datasets, and a mechanistically direct link (Clotrimazole targets Candida, the pathogen in 70–90% of VVC cases) make this an immediately actionable candidate. The Guardrails caveat: the “vulvovaginitis” ICD category includes bacterial vaginosis and trichomoniasis where Clotrimazole is ineffective — product labeling must specify the candidal subtype. Notably, the repurposing rationale identifies this as Clotrimazole’s core indication, meaning any Canadian registration effort is a label expansion or market entry, not a novel repurposing.
Postmenopausal atrophic vaginitis (Rank 3 TxGNN, L4): Weak mechanistic link and no direct supporting evidence. Only one indirectly related trial was retrieved. This remains a research question pending primary driver characterization (estrogen deficiency vs. secondary Candida colonization).

To proceed, the following is needed:

Verify Canada market status via Health Canada DPD — resolve the 0-DIN data gap before any regulatory strategy is defined
Retrieve the Health Canada product monograph (or TFDA package insert PDF) for key warnings, contraindications, and drug interactions — currently a blocking data gap
Retrieve MOA data from DrugBank API (DB00257) to complete mechanistic sections for all three predicted indications
For acne: determine whether the intended clinical question is Malassezia folliculitis (stronger mechanistic case, potentially actionable) vs. acne vulgaris (weak case, Hold maintained) before committing further resources
For vulvovaginitis: if Canesten® is already registered in Canada, confirm whether the label explicitly covers candidal vulvovaginitis and evaluate whether a new DIN or label variation is needed; if not registered, assess the regulatory pathway for a vaginal antifungal product
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.